The US Food and Drug Administration (FDA) has approved ustekinumab -kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...

Prices for the first 10 drugs negotiated by Medicare fell from their initial net prices, but all drugs except one remained ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen’s STELARA), Samsung commenced the ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

Biocon Biologics Ltd announced today that the U.S. Food and Drug Administration has approved YESINTEK™ (Ustekinumab-kfce), a ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) ...

Biocon Biologics the biosimilars company and subsidiary of Indian drugmaker Biocon, has announced that the US Food and Drug ...

US FDA approves Biocon Biologics’ Yesintek, Bmab 1200 biosimilar to J&J's Stelara: Our Bureau, Bengaluru Monday, December 2, 2024, 16:15 Hrs [IST] Biocon Biologics subsidiary of ...